A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals - Wikidata - wikimedia - TriplyDB

A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals

A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals

http://www.wikidata.org/entity/Q34091925

about

Vaccination for hepatitis C virus: closing in on an evasive target Dendritic cell-based immunity and vaccination against hepatitis C virus infection Candidate hepatitis C vaccine trials and people who inject drugs: challenges and opportunities Dendritic cell-mediated, DNA-based vaccination against hepatitis C induces the multi-epitope-specific response of humanized, HLA transgenic mice.DCs pulsed with novel HLA-A2-restricted CTL epitopes against hepatitis C virus induced a broadly reactive anti-HCV-specific T lymphocyte response.Induction of multi-functional T cells in a phase I clinical trial of dendritic cell immunotherapy in hepatitis C virus infected individuals.Mature autologous dendritic cell vaccines in advanced non-small cell lung cancer: a phase I pilot study.Dual Effects of Cellular Immunotherapy in Inhibition of Virus Replication and Prolongation of Survival in HCV-Positive Hepatocellular Carcinoma Patients.Persistent hepatitis C viral replication despite priming of functional CD8+ T cells by combined therapy with a vaccine and a direct-acting antiviral Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans.High, broad, polyfunctional, and durable T cell immune responses induced in mice by a novel hepatitis C virus (HCV) vaccine candidate (MVA-HCV) based on modified vaccinia virus Ankara expressing the nearly full-length HCV genome.Mobilizing monocytes to cross-present circulating viral antigen in chronic infection.Mixing the right hepatitis C inhibitor cocktail.Dendritic cells in hepatitis C infection: can they (help) win the battle?Dendritic cells in the pathogenesis and treatment of human diseases: a Janus Bifrons?Advances in hepatitis C virus vaccines, part two: advances in hepatitis C virus vaccine formulations and modalities.Complete definition of immunological correlates of protection and clearance of hepatitis C virus infection: a relevant pending task for vaccine development.Hepatitis C virus-mediated modulation of cellular immunity.Future considerations for dendritic cell immunotherapy against chronic viral infections.Progress in the development of vaccines for hepatitis C virus infection.Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection.Tolerogenic dendritic cell therapy in organ transplantation.Broadening CD4+ and CD8+ T Cell Responses against Hepatitis C Virus by Vaccination with NS3 Overlapping Peptide Panels in Cross-Priming Liposomes."Hep C, where art thou": What are the remaining (fundable) questions in hepatitis C virus research?Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection.Enhanced T cell responses against hepatitis C virus by ex vivo targeting of adenoviral particles to dendritic cells.Global elimination of hepatitis C virus infection: Progresses and the remaining challenges.Immunotherapy with interferon-α-induced dendritic cells for chronic HCV infection (the results of pilot clinical trial).Dendritic cells: active and passive players in therapy of human diseases.

P2860

Q22305922-CD19D134-4FFD-4DD2-B83D-FFD387D917C6 Q26828003-438D170F-78F2-4E84-923C-74527217E81F Q30226978-66230C98-059C-4A25-8B58-C68A08C669D1 Q34028154-9C77DF2C-C74C-466A-940A-6C2ACFE3188C Q34305417-4003873B-CEE8-4272-B3FD-A1DE1E8F052F Q34384186-F128FEA8-BE6E-44B9-B43A-AB6B21140822 Q35102873-93DA9D2A-1BA7-4134-8971-F179A3AB2F09 Q36741778-1EF0B414-8813-4C3F-BBFD-C6B2D80649E6 Q36823319-8FC098B4-2917-4221-BCD8-D21605C2E83A Q36828161-E86B07CB-5091-4675-87D5-1BE320AE9B10 Q36978998-5EAFADA1-435B-4519-95F1-52BCD0BAF478 Q37123862-A56137AE-8375-40CD-B99D-A0FDF5453A14 Q37812189-C4895F4E-F6C5-489A-BD07-4D793AEA47B4 Q37843841-FD554A41-2028-4D4E-A18C-5BB6A4F63455 Q37945301-5B9ACEF7-8BC8-443C-8AAF-CFEAF48BBDEC Q37997825-E5986B0F-AB93-496F-8848-E8B20C17578B Q38010203-A894B590-1C91-4BD5-8BC3-8D772A984BD6 Q38036576-CA686272-9E0B-49E4-8141-B413EC6CBF94 Q38204769-9923FB0D-D1D3-478B-8C01-8F960A021A1E Q38635596-FD14099E-DB90-459B-9E94-D0A2E8ED119D Q39000980-9BBE1A5A-6D38-4006-A070-1CF1635CE447 Q39013872-EC2DCD36-37B9-48DE-BCC9-0024C7CF904C Q40226233-6ADAA2BC-4000-45E5-9462-DF9CF2EEAE57 Q40536482-04BD3194-A318-4EAA-9A0F-0E6A36073DDF Q40588780-B0FD3DEF-CD55-4EBE-AFA8-4A46D227FEFD Q43035679-0A2D3566-7702-4DB1-8C81-191F6C0E37EB Q47274792-94BF6D20-88A2-4468-89C1-CB9941C1E105 Q47375197-137740D2-B6FD-494F-92AC-0F6B13A64E40 Q48356067-952773F5-582B-46C0-BE27-241042ED9798

P2860

A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals

http://www.wikidata.org/entity/Q34091925

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals

@ast

A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals

@en

A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals

@nl

type

label

A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals

@ast

A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals

@en

A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals

@nl

prefLabel

A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals

@ast

A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals

@en

A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals

@nl

P1433

Q34091925-4F2A6E6D-931E-4476-88A7-35D0BFE9D7A1

P1476

Q34091925-4095B29C-9CB5-4945-ACE3-AE3EE6009C94

P2093

Q34091925-07AB0FCA-D698-4623-8CC2-CB9BECDD4F54

Q34091925-12FB0D5F-46B6-4017-9BAE-2175A33BBB4B

Q34091925-342A3DB2-40D4-4A78-A969-8D077B5513EB

Q34091925-445C50B9-E5FC-4A2B-B680-0C220E6F2CF1

Q34091925-6085E901-1403-47BE-94EE-CA58756520D6

Q34091925-7C07A20C-D757-4D95-B0C2-FA901823EA65

Q34091925-7C12C034-A5FB-4E78-AA02-F9736AC1E2C0

Q34091925-B87F1A87-192B-42D0-850F-37B09C433A4E

Q34091925-C70D3049-5DE7-454F-B26E-C43E047C7F9B

Q34091925-CE164157-C6D6-4185-919D-9A1890DD5B56

P2860

Q34091925-05B0F813-F027-4C7C-B5D4-1FE1A8ADCB8F

Q34091925-0F671D79-E0C3-488A-9C7B-F8559ACAC627

Q34091925-11046848-E1B2-44C5-8CE2-DCDA4E06F508

Q34091925-13519014-2859-429C-8F32-9933242AD0CE

Q34091925-19AF5FD6-A0D1-4C68-8FE5-4BD9B8724EB3

Q34091925-1C9F6756-8CB9-464D-A040-7CAE784F77BB

Q34091925-2771DD5A-64CE-4C16-9D8E-6CFFB44FE4FA

Q34091925-2B6DEC5C-AF6F-44BB-ADA6-89EBE075F7E4

Q34091925-2BE7EA53-4620-4F2C-8B40-3214D63D7636

Q34091925-351F080D-35B9-4A68-BB83-95E2BC1056BE

P304

Q34091925-2DD986C1-CE73-4E50-A9A5-721C03F4C1EA

P31

Q34091925-29A51371-9CD4-4DA8-9B1C-DF3C33BD3B7C

P356

Q34091925-7FAFDBF4-7B4E-4BC9-81C9-242AD024020C

P433

Q34091925-E32F3B26-E5CE-4550-8C1D-383AEE1A27D8

P478

Q34091925-AC35CF6E-9922-40CB-AD27-4B34D3DECDBE

P50

Q34091925-3B160E5D-DC06-45FF-B903-AE3554C72DA1

Q34091925-5479C622-6310-410C-A2A4-41EFD09AFCE5

Q34091925-5BF4D18C-4B74-42FB-BDCD-CFC274E3C618

Q34091925-8438BFF7-1F9C-48E9-A627-13F63EDC61C7

Q34091925-D5058F3A-0FD9-420C-8251-7F36D6806F74

Q34091925-D592E48F-E4B8-4767-AED7-255A0765F866

P577

Q34091925-E49CD3C9-309D-4A90-AA3E-A5B7DF2AB1B3

P5875

Q34091925-3C3CE043-5E34-4321-8B75-B310ADE6B8B3

P698

Q34091925-93CFF96B-1041-4A4D-96E5-F9C110944A64

P921

Q34091925-D53837F8-31A8-4E4F-B4B4-F233D59B7FA4

Q34091925-F500FCDA-0185-40B7-8EFA-F350A63E13DA

P932

Q34091925-65EC94A0-C9FE-4B83-B33E-5331049A50E0

P356

J.JHEP.2010.05.007

P1433

Journal of Hepatology

P1476

A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals

@en

P2093

Derek Hart

http://www.w3.org/2001/XMLSchema#string

Dominic M Wall

http://www.w3.org/2001/XMLSchema#string

Emily M Y Eriksson

http://www.w3.org/2001/XMLSchema#string

Eric J Gowans

http://www.w3.org/2001/XMLSchema#string

H Miles Prince

http://www.w3.org/2001/XMLSchema#string

Irene Dinatale

http://www.w3.org/2001/XMLSchema#string

Jude Moloney

http://www.w3.org/2001/XMLSchema#string

Kathryn Jones

http://www.w3.org/2001/XMLSchema#string

Maureen Loudovaris

http://www.w3.org/2001/XMLSchema#string

Philippe A Latour

http://www.w3.org/2001/XMLSchema#string

P2860

Virus-Specific CD8+ Lymphocytes Share the Same Effector-Memory Phenotype but Exhibit Functional Differences in Acute Hepatitis B and C

Prophylactic and therapeutic vaccination with dendritic cells against hepatitis C virus infection

Liver-Infiltrating Lymphocytes in Chronic Human Hepatitis C Virus Infection Display an Exhausted Phenotype with High Levels of PD-1 and Low Levels of CD127 Expression

Inhibition of Natural Killer Cells through Engagement of CD81 by the Major Hepatitis C Virus Envelope Protein

Binding of the Hepatitis C Virus Envelope Protein E2 to CD81 Inhibits Natural Killer Cell Functions

Genetic drift in hypervariable region 1 of the viral genome in persistent hepatitis C virus infection

Dendritic cells and the control of immunity

Determinants of viral clearance and persistence during acute hepatitis C virus infection

Evasion of intracellular host defence by hepatitis C virus

Adaptive immune responses in acute and chronic hepatitis C virus infection

P304

599-607

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JHEP.2010.05.007

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P50

Lorena E. Brown

Rosemary L Sparrow

P577

2010-06-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45405994

http://www.w3.org/2001/XMLSchema#string

P698

20667615

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

2930140

http://www.w3.org/2001/XMLSchema#string